This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Madrigal Pharmaceuticals, Inc.
Drug Names(s): VEGF-2 Coronary Artery Disease Product
Vascular Genetics and Human Genome
In October 1997, Vascular Genetics secured an exclusive, worldwide license from Human Genome Sciences to make, use and sell products covered by certain patents owned by Human Genome Sciences, or otherwise using the VEGF-2 technology, in the gene therapy treatment of vascular disease. The license agreement requires CorAutus to make royalty payments to Human Genome Sciences based on certain percentages of net revenue from sales of products covered by the licensed technologies and from sublicensing of the licensed technologies.
CorAutus and Vical
In February 2000, CorAutus obtained an exclusive, worldwide license from Vical to develop, make, use and sell products using VEGF-2 and covered by certain patents and patent applications owned by Vical, relating to gene therapy delivery methods, for the treatment or prevention of disease in humans using gene therapy. The license agreement requires CorAutus to make royalty payments to...See full deal structure in Biomedtracker
Partners: GlaxoSmithKline plc Vical, Inc. Boston Scientific Corporation
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: